Home Alzheimer’s Disease Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Results of the...

Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Results of the Phase III ASPEN Trial

Results from the randomized phase III ASPEN trial, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, indicated that zanubrutinib (Brukinsa) was associated with a higher complete response or very good partial response (CR+VGPR) rate and demonstrated clinically meaningful advances in safety and tolerability compared to ibrutinib (Imbruvica) in patients with Waldenströmmacroglobulinemia.

However, the results of this trial were not statistically significant, and further follow-up is needed to establish other endpoints such as progression-free survival and overall survival between the 2 arms.

In an interview with CancerNetwork®, Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, of the Peter MacCallum Cancer Centre, discussed the study design of ASPEN and the results presented at ASCO.

Transcription:

So, the phase III Aspen study is a study…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments